The therapeutic potential of novel antiangiogenic therapies

Area of Science:

• Oncology
• Pharmacology
• Biomedical Engineering

Background:

• Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
• Targeting angiogenesis is a validated strategy in cancer treatment, with several drugs approved.
• Numerous novel antiangiogenic agents are under investigation to improve efficacy and overcome resistance.

Purpose of the Study:

• To review current antiangiogenic drugs in clinical trials for cancer treatment.
• To explore emerging antiangiogenic strategies, including gene therapy, vaccines, and radioligands.
• To discuss challenges in clinical trial design, dosing, toxicity, and resistance, and propose solutions.

Main Methods:

• Comprehensive literature review of preclinical and clinical studies on antiangiogenic agents.
• Analysis of data from completed Phase III clinical trials.
• Exploration of novel therapeutic modalities and their potential applications.

Main Results:

• A wide array of antiangiogenic drugs targeting vascular endothelial growth factor (VEGF), its receptors, integrins, and matrix metalloproteinases are in various stages of clinical trials.
• Emerging strategies like gene therapy, cancer vaccines, and antiangiogenic radioligands show promise.
• Phase III trials have provided valuable insights into the efficacy and limitations of current antiangiogenic therapies.

Conclusions:

• Significant progress has been made in developing antiangiogenic therapies for cancer.
• Overcoming obstacles related to trial design, optimal dosing, managing toxicities, and addressing drug resistance is critical for clinical success.
• Future research should focus on innovative approaches and combination strategies to enhance antiangiogenic therapy outcomes.